Idorsia

Idorsia UK represents the British operations of the Swiss biopharmaceutical company developing innovative medicines for unmet medical needs in sleep medicine, cardiovascular disease, and rare diseases. The company’s portfolio includes QUVIVIQ (daridorexant), a dual orexin receptor antagonist for the treatment of chronic insomnia in adults.